Recalibration of implantable brain-computer interfaces to enable long-term independent use - a systematic review

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: No quantitative effect size reported; narrative finding that ECoG-based iBCIs generally require less frequent recalibration than MEA-based devices, and automatic recalibration methods reduce or eliminate the need for specialist staff assistance

• Primary Outcome: Characterisation of recalibration practices across iBCI studies, including frequency, duration, staff requirements, and location; assessment of strategies enabling long-term independent use

• Nnt Or Sensitivity: Not applicable in this context; no NNT, sensitivity, specificity, or hazard ratio reported. Key directional finding: automatic recalibration methods enable patient-independent device maintenance, whereas manual recalibration requires specialist research team involvement, representing the highest dependency burden

• Confidence Interval: Not applicable — no meta-analysis performed; no confidence intervals reported

Clinical Application

Direct clinical implementation of specific recalibration protocols is not yet feasible based on this review alone. The evidence base consists of heterogeneous research-grade studies. However, the review provides a practical framework for clinicians and device teams to evaluate recalibration burden when selecting iBCI systems or designing clinical protocols. Automatic recalibration approaches represent the most feasible pathway to home-based independent use, but require further validation in real-world settings outside research centres. In Australia, iBCIs remain investigational devices with no current TGA market authorisation for commercial implantable BCI systems (as of mid-2026). The Therapeutic Goods Administration (TGA) would require robust evidence of long-term safety and performance stability — including recalibration requirements — before regulatory approval. The findings of this review are directly relevant to future TGA submissions and to the design of Australian first-in-human trials. The RACGP and relevant specialist colleges (ANZAN, AAN) have not yet issued guidelines on iBCI management. PBS listing is not applicable at this stage. Australian neurosurgical and rehabilitation centres (e.g., Royal Melbourne Hospital, Prince of Wales Hospital) involved in emerging iBCI programmes should note the recalibration burden implications for staffing models and patient selection. The National Disability Insurance Scheme (NDIS) framework may eventually need to accommodate iBCI maintenance costs, including recalibration support services. Adults with acquired motor impairments (e.g., amyotrophic lateral sclerosis, spinal cord injury, stroke-related tetraplegia) who are candidates for or current users of implantable brain-computer interface devices. The findings are most directly applicable to patients enrolled in research trials or early-access programmes at specialist neurotechnology centres.

Abstract

Background.Implantable brain-computer interfaces (iBCIs) decode neural signals to generate command signals for effector devices to restore lost functions, such as movement or speech. However, maintaining device performance over time requires recalibration of decoding algorithms due to inherent instability in neural signals.Objective.To systematically review recalibration procedures in iBCIs for patients with motor impairments, focusing on the clinical implications of recalibration requirements and strategies which can enable long-term, independent use.Approach.A systematic search was conducted across EMBASE, MEDLINE, and CINAHL databases to identify studies involving recalibration of iBCIs. Data on recalibration frequency, duration, staff requirements, and location were extracted and analyzed.Main results.Recalibration practices varied widely amongst studies and were typically performed according to predetermined study protocols, rather than practical need following deteriorating device performance. Common practices include manual recalibration requiring a specialist research team, semi-automatic recalibration which could be performed by a non-specialist caregiver, and automatic recalibration methods whereby patients did not require assistance. Devices utilizing electrocorticography (ECoG) recording arrays generally required less frequent recalibration compared to those using microelectrode arrays (MEAs). Extended independent use was more frequently reported with ECoG-based iBCIs.Significance.Reducing recalibration frequency or complexity can improve patient autonomy, which is crucial for enhancing long-term independent iBCI use in home and clinical settings. ECoG iBCIs typically have a low recalibration burden due to inherent signal stability. Conversely, MEA iBCIs typically involve a higher recalibration burden, though recent studies have reduced this by incorporating spectral data and continuously updating models. Despite this progress, recalibration procedures are often not fully defined in iBCI studies, and where they are, they usually relate to the study protocol rather than the clinically meaningful recalibration requirement due to worsening device performance. Future studies should continue to develop user-friendly recalibration procedures and outline the clinically relevant recalibration requirements where possible.

References

1. 1.Swanson, E., Dohle, E., Bashford, L., Horsfall, H. L., Jovanovic, L., Muirhead, W. R., & Brannigan, J. F. M. (2026). Recalibration of implantable brain-computer interfaces to enable long-term independent use - a systematic review. Journal of Neural Engineering. https://doi.org/10.1088/1741-2552/ae7694